Sign In
Buy FBIO
$2.61
-0.0400 (-1.51%)
At Close: Jun 03, 2026
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates
02:25pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 20% and 23.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022
12:52pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022
08:52am, Thursday, 03'rd Nov 2022
Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on effic
Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences
08:30am, Tuesday, 04'th Oct 2022
SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and c
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
12:00pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
Company also strengthens Board of Directors with addition of Stanford Professor Vibeke Strand, M.D., MACR, FACP Company also strengthens Board of Directors with addition of Stanford Professor Vibeke S
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08:30am, Thursday, 08'th Sep 2022
MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, develop
Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea
12:30pm, Tuesday, 30'th Aug 2022 GlobeNewswire Inc.
Topline data expected in the first half of 2023 Topline data expected in the first half of 2023
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates
09:45pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
08:30pm, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates
06:49pm, Thursday, 11'th Aug 2022
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates
12:45pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -18.75% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript
09:05pm, Tuesday, 09'th Aug 2022
Journey Medical Corporation (NASDAQ:FBIO ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Pa
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
08:01pm, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021
Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out for
02:00pm, Monday, 08'th Aug 2022 Zacks Investment Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
